These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 24717427)
1. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Musiime V; Cook A; Kayiwa J; Zangata D; Nansubuga C; Arach B; Kenny J; Wavamunno P; Komunyena J; Kabamba D; Asiimwe AR; Mirembe G; Abongomera G; Mulenga V; Kekitiinwa A; Kityo C; Walker SA; Klein N; Gibb DM; Antivir Ther; 2014; 19(3):269-76. PubMed ID: 24717427 [TBL] [Abstract][Full Text] [Related]
2. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. Kumar PN; Rodriguez-French A; Thompson MA; Tashima KT; Averitt D; Wannamaker PG; Williams VC; Shaefer MS; Pakes GE; Pappa KA; HIV Med; 2006 Mar; 7(2):85-98. PubMed ID: 16420253 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Bwakura-Dangarembizi M; Musiime V; Szubert AJ; Prendergast AJ; Gomo ZA; Thomason MJ; Musarurwa C; Mugyenyi P; Nahirya P; Kekitiinwa A; Gibb DM; Walker AS; Nathoo K; Pediatr Infect Dis J; 2015 Feb; 34(2):e23-31. PubMed ID: 25068287 [TBL] [Abstract][Full Text] [Related]
4. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209 [TBL] [Abstract][Full Text] [Related]
6. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876 [TBL] [Abstract][Full Text] [Related]
7. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P; Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107 [TBL] [Abstract][Full Text] [Related]
9. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470 [TBL] [Abstract][Full Text] [Related]
10. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606 [TBL] [Abstract][Full Text] [Related]
11. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H; Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492 [TBL] [Abstract][Full Text] [Related]
12. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF; HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661 [TBL] [Abstract][Full Text] [Related]
13. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647 [TBL] [Abstract][Full Text] [Related]
14. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA; JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385 [TBL] [Abstract][Full Text] [Related]
15. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563 [TBL] [Abstract][Full Text] [Related]
17. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687 [TBL] [Abstract][Full Text] [Related]
18. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421 [TBL] [Abstract][Full Text] [Related]
19. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573 [TBL] [Abstract][Full Text] [Related]
20. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A; J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]